奧基生技股份有限公司
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Developing genetic testing products related to drug responses and providing pharmacogenomic testing services for precision medicine.
The content above was translated by Ai
Founded Year
2018
Unified Business No.
50897831
Status
Active
Number of Employees
0
Total Paid-in
Capital
5,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
PGx74: A screening platform for drug allergies that develops genetic testing products related to drug responses and provides pharmacogenomic testing services related to precision medicine. The goal is not only to meet the needs of regular health checkup clients for allergy testing of commonly used drugs, but also to satisfy the testing needs of patients regarding drug responses for specific diseases, thereby accelerating the pace of entering the era of personalized medicine.
The content above was translated by Ai
